Characterisation of CGRP receptors in the human isolated middle meningeal artery

Life Sciences

Volumn 79, Issue 3, 2006, Pages 265-271

  Gupta, Saurabh ^a   Mehrotra, Suneet ^a   Avezaat, Cees J J ^a   Villalón, Carlos M ^b   Saxena, Pramod R ^a   MaassenVanDenBrink, Antoinette ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Cinvestav Sede sur   (Mexico)

Author keywords

Cys (Et)2,7 h CGRP; BIBN4096BS; CGRP receptors; h CGRP; h CGRP8 37; Human meningeal artery; Migraine

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE[8-37]; LIGAND; OLCEGEPANT;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MALE; MENINGEAL ARTERY; MIGRAINE; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASODILATATION;

CALCITONIN GENE-RELATED PEPTIDE; HUMANS; LIGANDS; MENINGEAL ARTERIES; MIGRAINE DISORDERS; PEPTIDE FRAGMENTS; PIPERAZINES; QUINAZOLINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASODILATION; VASODILATOR AGENTS;

EID: 33744493383     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.003     Document Type: Article

References (32)

1. Arulmani U., MaassenVanDenBrink A., Villalón C.M., and Saxena P.R. Calcitonin gene-related peptide and its role in migraine pathophysiology. European Journal of Pharmacology 500 (2004) 315-330
2. Arunlakshana O., and Schild H.O. Some quantitative uses of drug antagonists. British Journal of Pharmacology 14 (1959) 48-58
3. Batenburg W.W., Garrelds I.M., Bernasconi C.C., Juillerat-Jeanneret L., van Kats J.P., Saxena P.R., and Danser A.H.J. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109 (2004) 2296-2301
4. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., and Eberlein W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. British Journal of Pharmacology 129 (2000) 420-423
5. 2 in vitro bioassays. Canadian Journal of Physiology and Pharmacology 75 (1997) 671-676
6. Durham P.L. CGRP-receptor antagonists-a fresh approach to migraine therapy?. New England Journal of Medicine 350 (2004) 1073-1075
7. Edvinsson L., Alm R., Shaw D., Rutledge R.Z., Koblan K.S., Longmore J., and Kane S.A. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. European Journal of Pharmacology 434 (2002) 49-53
8. Evans B.N., Rosenblatt M.I., Mnayer L.O., Oliver K.R., and Dickerson I.M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. Journal of Biological Chemistry 275 (2000) 31438-31443
9. Goadsby P.J., and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology 33 (1993) 48-56
10. Goadsby P.J., Edvinsson L., and Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology 28 (1990) 183-187
11. Gupta S., Mehrotra S., Villalón C.M., Garrelds I.M., de Vries R., van Kats J.P., Sharma H.S., Saxena P.R., and MaassenVanDenBrink A. Characterisation CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. European Journal of Pharmacology 530 (2006) 107-116
12. Hargreaves R.J., and Shepheard S.L. Pathophysiology of migraine-new insights. Canadian Journal of Neurological Science 26 Suppl. 3 (1999) S12-S19
13. Henkes H., May A., Kuhne D., Berg-Dammer E., and Diener H.C. Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography. Cephalalgia 16 (1996) 224-230
14. Jansen-Olesen I., Jorgensen L., Engel U., and Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. European Journal of Pharmacology 481 (2003) 207-216
15. Juaneda C., Dumont Y., and Quirion R. The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends in Pharmacological Sciences 21 (2000) 432-438
16. Luebke A.E., Dahl G.P., Roos B.A., and Dickerson I.M. Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proceedings of the National Academy of Sciences of USA 93 (1996) 3455-3460
17. MaassenVanDenBrink A., Reekers M., Bax W.A., Ferrari M.D., and Saxena P.R. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98 (1998) 25-30
18. MaassenVanDenBrink A., van den Broek R.W.M., de Vries R., Bogers A.J.J.C., Avezaat C.J.J., and Saxena P.R. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55 (2000) 1524-1530
19. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., Solari R., Lee M.G., and Foord S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
20. Moreno M.J., Abounader R., Hebert E., Doods H., and Hamel E. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 42 (2002) 568-576
21. Nyborg N.C., Baandrup U., Mikkelsen E.O., and Mulvany M.J. Active, passive and myogenic characteristics of isolated rat intramural coronary resistance arteries. Pflügers Archives 410 (1987) 664-670
22. Olesen J., Diener H.C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., and Lesko L.M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine 350 (2004) 1104-1110
23. Oliver K.R., Wainwright A., Edvinsson L., Pickard J.D., and Hill R.G. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. Journal of Cerebral Blood Flow and Metabolism 22 (2002) 620-629
24. Poyner D.R., Sexton P.M., Marshall I., Smith D.M., Quirion R., Born W., Muff R., Fischer J.A., and Foord S.M. International Union of Pharmacology: XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacological Reviews 54 (2002) 233-246
25. Quirion R., Van Rossum D., Dumont Y., St-Pierre S., and Fournier A. Characterization of CGRP1 and CGRP2 receptor subtypes. Annals of the New York Academy of Sciences 657 (1992) 88-105
26. Sams A., Knyihar-Csillik E., Engberg J., Szok D., Tajti J., Bodi I., Edvinsson L., Vecsei L., and Jansen-Olesen I. CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes. European Journal of Pharmacology 408 (2000) 183-193
27. Sheykhzade M., Lind H., and Edvinsson L. Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries. British Journal of Pharmacology 143 (2004) 1066-1073
28. Tfelt-Hansen P., De Vries P., and Saxena P.R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60 (2000) 1259-1287
29. 8-37. British Journal of Pharmacology 136 (2002) 120-126
30. 8-37 antagonize the relaxant effects of alpha-CGRP more than those of beta-CGRP in human extracranial arteries. Naunyn-Schmiedeberg's Archives of Pharmacology 371 (2005) 383-392
31. Villalón C.M., Centurión D., Valdivia L.F., De Vries P., and Saxena P.R. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proceedings of the Western Pharmacology Society 45 (2002) 199-210
32. 2,7]hCGRP-preferring receptor. European Journal of Pharmacology 400 (2000) 313-319